Memorial Sloan Kettering Cancer Center

Where you’re treated first, matters. To make an appointment: 877-871-9362

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

We're excited to share Memorial Sloan Kettering Cancer Center (MSK)'s bold new advertising campaign “This Is What We Do.”

From a jazz musician whose life was saved by precision oncology, to a prostate cancer patient who has become an advocate for early detection, the stories we share throughout this campaign reflect our shared mission and the extraordinary outcomes we achieve together.

🔹 This is treatment on a cellular level. ​

🔹 This is care on a personal level. ​

🔹 This is hope on another level. ​

When someone receives a cancer diagnosis, we want them to know exactly what to do next: come to MSK. And when patients choose MSK, they’re choosing better, longer lives.

Learn more: https://t.co/SOGuFiUIGs

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

🚨 The @US_FDA has approved datopotamab deruxtecan (Dato-DXd) for patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy.

The approval was based on results from the international Tropion-Breast02 clinical trial, led in the U.S. by MSK breast medical oncologist Dr. Tiffany Traina. Learn more: https://t.co/LWY0SMzD9n

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Spotlighting research from MSK gynecologic medical oncologist and #ASCO26 Conquer Cancer grant recipient @AliSchram ⬇️

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

By focusing on genetic blueprints instead of tumor locations, Conquer Cancer grant recipient Dr. Alison Schram unlocked a historic FDA "double win" for rare, aggressive cancers. 🔬 Early-career funding accelerates life-changing discoveries. Read how her targeted therapy research is giving patients like Ahmet their lives back: https://t.co/Ee0Pqhx3m7

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK researchers are helping advance #MorPhiC, an international effort to determine the biological functions of the roughly 20,000 protein-coding genes in the human genome.

The work aims to transform the human genome from a list of parts into an instruction manual, helping researchers better understand what our genes do and how they shape human development.

Learn more about how MSK researchers are contributing to this effort: https://t.co/gUcG18N2WA

[Elizabeth McKenna @ElizSMcKenna]

Now in @CD_AACR: Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-related Survival - by Justin Jee, @SawyersLabMSKCC, @nikolausschultz, et al. @MSKCancerCenter - these findings suggest that the previously reported survival advantage may be explained by selection bias.

[Michael May @MichaelMayMD]

Already giving patients daraxonrasib off trial only 21 days after the practice-changing results were presented at @ASCO 2026. Thank you to @MSKCancerCenter and @RevMedicines for allowing us to fill this unmet need safely and efficiently. @EileenMOReilly @CentralParkWMD @CpcrMsk

[Coach Matt Rotonda @rotonda21]

To Linds: I love you, and I never blinked.

Lindsay rang the bell at 10:55AM EST at @MSKCancerCenter.

4 months- unexpected diagnosis, surgery, radiation… behind us because you are a champion.

To all who are fighting, or know someone who is… we see you. We support you.

[HemeHub @HemeHub]

📚 🚀Catch up on the latest insights in Multiple Myeloma from our session with Saad Z. Usmani, MD (@szusmani) and Adeel Khan, MD (@khancology)!

➡️Watch the full session: https://t.co/0whzv3DU5l

#MultipleMyeloma #PlasmaCellDisorders #Hematology #Oncology #MedicalEducation #PatientCare #Immunotherapy #CellTherapy #NovelTherapies #ClinicalTrials #HemeHub #HematologyEducation
@MSKCancerCenter @UTSWHemeOnc @MM_Hub @llmcongress @theMMRF @RareDiseases

[MSK Department of Medicine @MSK_DeptOfMed]

A new study by @RShouval and team evaluated the frequency of second primary malignant neoplasms among those with #Lymphoma or #Myeloma who received T-cell–engaging bispecific antibodies. @MSKCancerCenter

Learn more: https://t.co/IUIbezTneN

[Selwyn M. Vickers @DrVickersMSK]

On Juneteenth we honor a defining moment in our nation’s history and reflect on the ongoing work of expanding opportunity, dignity, and justice for all. I am grateful for the many colleagues, patients, and community partners who help us move forward with purpose and compassion.

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Congratulations to MSK gastrointestinal medical oncologist @EileenMOReilly on being honored with the Hope Through Compassion Award from the @lustgartenfdn. The award recognizes her dedication to patients and her leadership in developing innovative clinical research for #pancreaticcancer.

Watch to learn more about her approach to advancing pancreatic cancer research: https://t.co/ojuy5H8eyy

[Francesco Maura @FrancescoMaura4]

Together with @RossFirestone and @szusmani
we are happy to share our thoughts on SUCCESSOR-2 clinical trial published few days ago on @TheLancet
#mmsm #mezigdomide @MSKCancerCenter @MSK_DeptOfMed https://t.co/P9RS5pWPFI

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Results from the phase 3 #RASolute302 trial found that #daraxonrasib significantly improved overall survival compared with chemotherapy in previously treated metastatic #pancreaticcancer.

Learn more about the findings and what MSK's @EileenMOReilly says they could mean for the future of pancreatic cancer treatment: https://t.co/w2NhrorSM3

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

🎉Congratulations to MSK pathologist Dr. Alexander Gitlin for being named a 2026 Pew-Stewart scholar!

Dr. Gitlin will uncover how cell signaling controls the nature and magnitude of inflammation in normal physiology and in disease, focusing on the intersection of inflammatory signaling and cell death pathways.

[The Pew Trusts @pewtrusts]

And finally, meet the 2026 Pew-Stewart scholars.

These five scientists are tackling some of cancer research’s biggest questions, from pioneering new strategies to engineering lifesaving treatments.

https://t.co/nXMJiOXc5U

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK scientists have uncovered a hidden role for RNA.

Researchers led by MSK molecular and cell biologist @Mayr_Christine found that #RNA can act as a protein chaperone, helping critical regulatory proteins fold into the correct shape as they are being made.

The findings reveal a previously unknown function of RNA and suggest this mechanism may be used by more than 2,700 human genes. Learn more: https://t.co/cAQybc7Dck

[ACS Journal Cancer @JournalCancer]

New editorial by Drs. Gleneara E. Bates-Pappas Jamie S. Ostroff of @MSKCancerCenter | Breaking barriers: Opt-out tobacco dependence treatment in oncology care

https://t.co/xHer8qjT9j

@OncoAlert

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

For years, patients with triple negative #breastcancer (#TNBC) have had limited treatment options beyond chemotherapy.

Now, based on results from the MSK-led TROPION-Breast02 trial, Dato-DXd was FDA approved in May 2026 as first-line therapy for adults with advanced HER2 negative breast cancer who have already received endocrine-based therapy and chemotherapy, making it the first TROP2-directed ADC to gain FDA approval as first-line in this patient population.

“Dato-DXd significantly improved overall survival for this challenging subtype of breast cancer, where historic median overall survival has been about 12 months,” said Dr. Tiffany Traina, lead and senior author of the study and MSK breast medical oncologist.

Read more about the study: https://t.co/hyXyMmbb7S

[Stanford Cancer Institute @StanfordCancer]

Can pancreatic cancer be “cold yet vaccinable”? @TheVinodLab from @MSKCancerCenter shares insights on RNA vaccines at the SCI Breakthroughs in Cancer Series. Watch the full seminar: https://t.co/urhTYigCPX #PancreaticCancer

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

🗓️ Save the date! Join MSK’s annual Survivorship Celebration: Resilience in Motion on June 12 at 4pm ET. This event features survivorship stories, wellness practice, and expert guidance to navigate life after cancer.

Featured speakers include: MSK integrative medicine specialist Dr. @JunMaoMD; MSK thoracic medical oncologist Dr. Cardinale Smith; and MSK exercise physiologist Dr. Jessica Scott, who will share science-based evidence to guide and manage survivorship.

Register here: https://t.co/gPF3qE01sQ

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK radiation oncologist Dr. Nancy Lee (@imtrlee) presented new findings at the 2026 @asco suggesting some people with HPV-related #throatcancer may be able to receive significantly lower doses of radiation while maintaining excellent outcomes.

The approach could help reduce treatment-related side effects while preserving effectiveness. Learn more: https://t.co/5cbHs2jQe0

[Melanoma Research Foundation @CureMelanoma]

#MRFResearchWednesday – we are honored to highlight Sarah Kim of @MSKCancerCenter, recipient of an MRF Medical Student Award, with funding support provided in Memory of Peter Looney and the Looney Legacy Foundation.

Sarah’s work titled, “Benign Dermoscopic Morphology by Skin Tone and Anatomic Site”, will create a diverse image database of benign skin lesions across all skin tones to improve diagnosis, reduce unnecessary biopsies and help ensure future AI tools work effectively for everyone.

Of her work, Sarah offers, “This research aims to build a diverse image database of benign skin lesions seen through dermoscopy, helping dermatologists better recognize these common skin findings across different skin tones and body sites. By improving our understanding of what benign lesions look like in diverse patients, we hope to support more accurate melanoma detection, reduce unnecessary biopsies, and help ensure that patients of all skin tones receive thoughtful, equitable skin cancer care."

To learn more about Sarah’s work, click here: https://t.co/oIwjtXbVwQ